If you have been reading about WADA prohibited list and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-04-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Fredric Sheldon Brandt (June 26, 1949 – April 5, 2015) was an American physician, researcher, lecturer, author, and radio host specializing in cosmetic dermatology. Among the first to use botulinum toxin ("botox") and fillers, Brandt was noted for his role in the FDA approval of numerous fillers and botulinum toxins for cosmetic use in the United States. Brandt, who hosted a radio show called Ask Dr. Brandt on SiriusXM radio and whose celebrity patients included Madonna, was called the "Baron of Botox" by W magazine and "King of Collagen" for using more botox and collagen than any other dermatologist in the world.
== External links == "Remifentanil". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on June 28, 2019. "Remifentanil Hydrochloride". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on August 29, 2021.
Technology companies have built electricity and artificial intelligence infrastructure to facilitate the AI boom of the 2020s. A 2025 report from the consulting firm McKinsey & Company estimated that by 2030, $2.7 trillion would be invested into AI infrastructure and data centres in the US, surpassing World War II's Manhattan Project every month. In January 2024, the International Energy Agency (IEA) released Electricity 2024, Analysis and Forecast to 2026. This is the first IEA report to make projections for data centres and power consumption by AI and cryptocurrency. The report states that power demand for these uses might double by 2026, with the additional power consumption equaling that of Japan. Power consumption by AI is responsible for an increase in fossil fuel use, and has delayed closings of obsolete, carbon-emitting coal energy facilities. A ChatGPT search involves 10 times as much electrical energy as a Google search. A 2024 Goldman Sachs research paper, AI Data Centers and the Coming US Power Demand Surge, found "US power demand (is) likely to experience growth not seen in a generation...." and forecasts that, by 2030, US data centres will consume 8% of US power, as opposed to 3% in 2022, presaging growth for the electrical power generation industry by a variety of means. Data centres' need for more and more electrical power is such that they might max out the electrical grid. The Big Tech companies counter that AI can be used to maximise the utilisation of the grid by all.
(2026), who also report evidence of overlap of intraspecific variation of Sus lydekkeri, Sus peii, Sus strozzi and the wild boar. A study on the phylogenetic relationships of extant and extinct ruminants, and on the impact of increased fossil taxon sampling on the results of analyses of timing of ruminant evolution, is published by Till & Smith (2026). Evidence of presence of fossil material of seven ruminant taxa at the Pliocene site of Jradzor (Armenia) is presented by Bukhsianidze (2026). Hartung & Böhme (2026) study changes in the skull of Dorcatherium naui during its ontogeny, interpreted as suggestive of similarities of life history characteristics of the studied tragulid and extant water chevrotain. A study on the composition of the late Middle Miocene tragulid assemblage from the Chinji Formation (Pakistan) and on the ecology of the studied tragulids is published by Nawaz et al. (2026). Piprek, Rams-Pociecha & Mizia (2026) consider evidence from the study of extant and extinct pecoran ruminants to be insufficient to definitively resolve the question whether the cranial appendages share a common evolutionary origin or whether they evolved independently in multiple pecoran lineages. A study on tooth enamel histology of Eotragus noyei and Procervulus cf. dichotomus from the Miocene site of els Casots (Vallès-Penedès Basin, Spain), providing probable evidence of fast life histories of the studied ungulates, is published by Cuccu et al. (2026).
Sources: en.wikipedia.org
=== Equipment === Commonly used equipment for resistance training include free weights—including dumbbells, barbells, and kettlebells—weight machines, and resistance bands. Resistance can also be generated by inertia in flywheel training instead of by gravity from weights, facilitating variable resistance throughout the range of motion and eccentric overload. Some bodyweight exercises do not require any equipment, and others may be performed with equipment such as suspension trainers or pull-up bars.
== Background == The elections were held less than a year after the July 1921 legislative elections, in which the Republican Liberal Party (PLR) had won a majority of votes. However, on 19 October 1921 ("the night of blood"), a military coup resulted in several republican figures being killed, including PLR prime minister António Granjo. On the night of blood, President António José de Almeida invested Manuel Maria Coelho as Prime Minister, but his government resigned on 3 November. On the same day, Carlos Maia Pinto became Prime Minister, but also resigned on 16 December. Francisco Cunha Leal then served as Prime Minister until the elections. The elections took place amidst instability and violence and were postponed four times before finally taking place on 29 January.
=== Lewis acid === SO3 is a strong Lewis acid readily forming adducts with Lewis bases. With pyridine, it gives the sulfur trioxide pyridine complex. Related adducts form from dioxane and trimethylamine.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.